18 CAMPUS BLVD., NEWTOWN SQUARE, PA
To Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results
Arrivent Unveils Firmonertinib Study Results for EGFR Mutant Lung Cancer at 2025 Lung Cancer Conference
Reports Second Quarter 2025 Financial Results
Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Arrivent Reports Positive Firmonertinib Study Results for EGFR Mutant Lung Cancer
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership